COVID-19 and acute kidney injury in German hospitals

2020

COVID-19 and AKI in Germany

4

5

6

7

8

Victor Walendy¹, Matthias Girndt¹, Daniel Greinert¹

10

11 ¹

Department of Internal Medicine II
Medical Faculty of the
Martin-Luther-University Halle-Wittenberg
Ernst-Grube-Straße 40
D-06120 Halle (Saale)
Germany

18

Corresponding author:

Victor.walendy@uk-halle.de

21

22 Abstract

23 Introduction

24 The SARS-CoV-2 pandemic is a major challenge for patients, healthcare professionals, and
25 populations worldwide. While initial reporting focused mainly on lung involvement, the
26 ongoing pandemic showed that multiple organs can be involved, and prognosis is largely
27 influenced by multi-organ involvement. Our aim was to obtain nationwide retrospective
28 population-based data on hospitalizations with COVID-19 and AKI.

29 Materials & Methods

30 We performed a query of G-DRG data for the year 2020 via the Institute for the hospital
31 remuneration system (Institut für das Entgeltsystem im Krankenhaus GmbH, InEK) data
32 portal and therefore included hospitalizations with a secondary diagnosis of RT-PCR proven
33 COVID-19 infection, aged over 15 years. We included hospitalizations with acute kidney
34 injury (AKI) stages 1 to 3. Age-specific and age-standardized hospitalization and in-hospital
35 mortality rates (ASR) per 100.000 person years were calculated, with the German
36 population of 2011 as the standard.

37 Results

38 In 2020, there were 16.776.845 hospitalizations in German hospitals. We detected 154.170
39 hospitalizations with RT-PCR proven COVID-19 diagnosis. The age-standardized
40 hospitalization rate for COVID-19 in Germany was 232,8 per 100.000 person years (95% CI
41 231,6-233,9). The highest proportion of hospitalizations associated with COVID-19 were in
42 the age group over 80 years. AKI was diagnosed in 16.773 (10,9%) of the hospitalizations

43 with COVID-19. The relative risk of AKI for males was 1,49 (95%CI 1,44-1,53) compared to
 44 females. Renal replacement therapy (RRT) was performed in 3.443 hospitalizations, 20,5%
 45 of the hospitalizations with AKI. For all hospitalizations with COVID-19, the in-hospital
 46 mortality amounted to 19,7% (n= 30.300). The relative risk for in-hospital mortality was 3,87
 47 (95%CI 3,80-3,94) when AKI occurred. The age-standardized hospitalization rates for COVID-
 48 19 took a bimodal course during the observation period. The first peak occurred in April
 49 (ASR 23,95 per 100.000 person years (95%CI 23,58-24,33)), hospitalizations peaked again in
 50 November 2020 (72,82 per 100.000 person years (95%CI 72,17-73,48)). The standardized
 51 rate ratios (SRR) for AKI and AKI-related mortality with the overall ASR for COVID-19
 52 hospitalizations in the denominator, decreased throughout the observation period and
 53 remained lower in autumn than they were in spring. In contrast to all COVID-19
 54 hospitalizations, the SRR for overall mortality in COVID-19 hospitalizations diverged from
 55 hospitalizations with AKI in autumn 2020.

56 Discussion

57 Our study for the first time provides nationwide data on COVID-19 related hospitalizations
 58 and acute kidney injury in Germany in 2020. AKI was a relevant complication and associated
 59 with high mortality. We observed a less pronounced increase in the ASR for AKI-related
 60 mortality during autumn 2020. The proportion of AKI-related mortality in comparison to the
 61 overall mortality decreased throughout the course of the pandemic.

62
 63

64 Introduction

65 The SARS-CoV-2 pandemic is a major challenge for patients, healthcare professionals, and
 66 populations worldwide. While initial reporting focused mainly on lung involvement, the
 67 ongoing pandemic showed that multiple organs can be involved, and prognosis is largely
 68 influenced by multi-organ involvement. According to published data, the kidney is the
 69 second most involved organ. In a study from the New York City area, 22,2% of hospitalized
 70 patients showed acute kidney injury (AKI)(1). A meta-analysis (2) confirmed the high AKI
 71 rate among COVID-19 patients. In contrast to this, there is also data with lower incidence of
 72 AKI(3,4) especially early analysis from Wuhan, China did not show high incidence rates of
 73 AKI (3–5). However, different definitions of AKI complicate comparability. In critically ill
 74 patients with COVID-19 as many as 55 to 90% experienced AKI (6–8), of whom 21 to 37%
 75 required renal replacement therapy (RRT) (6,8,9). The mortality rates of patients with acute
 76 kidney injury are significantly higher than in patients without AKI. In a study by Chan et al.
 77 (9), the in-hospital mortality was 50% among patients with, versus 8% among those without
 78 AKI. An analysis by Fisher et al. (8) found similar mortality rates (52% vs. 19.6%). In addition,
 79 the length of stay (LOS) was markedly prolonged when AKI occurred (9,10).

80 The German healthcare system offers comprehensive insurance coverage and, by
 81 international comparison, a high level of healthcare services. Throughout the COVID-19
 82 pandemic there were no apparent acute care resource limitations, and the hospital
 83 capacities were at their limit but not overwhelmed. Nationwide unselected data, especially
 84 covering a longer time interval is not available. There is one observational study, which
 85 included 10.021 hospitalizations (11). The data from this study was obtained from one

German health insurance company and covered a short period of time (from February 26 until April 19, 2020). In this study, AKI was not addressed.

Our aim was to obtain nationwide retrospective population-based data on hospitalizations with COVID-19 and AKI. Our query covered data from the year 2020 and contains, to our knowledge, the most comprehensive data regarding patients with COVID-19 and AKI in Germany.

Materials & Methods

Data Source

In accordance with the German Hospital Financing Act (KHG), a universal, performance-based remuneration system was introduced for general hospital services. The basis for this is the German-Diagnosis Related Groups system (G-DRG system), whereby each inpatient case of treatment is remunerated by means of a corresponding DRG rate. All hospitals submit their hospitalization data to the Institute for the hospital remuneration system (Institut für das Entgeltsystem im Krankenhaus GmbH, InEK). After submission, a plausibility control of the data is carried out by InEK. The submission of hospitalization data is mandatory for reimbursement of hospital stays. This leads to a strong incentive for hospitals to supply complete data, covering virtually every hospital in Germany. The transferred data include information on age, sex, discharge type, primary and secondary ICD-10-GM(12) coded diagnosis (International Classification of Diseases, 10th Edition, German Modification Version 2020) and performed operations and procedures (Operationen- und Prozedurenschlüssel Version 2020, OPS) (13). We performed a query of G-DRG data for the year 2020 via the InEK data portal (<https://datenbrowser.inek.org/>). The InEK data are

108 available in aggregated form, so that differentiation by federal state is not possible.
109 Differentiation by age can only be made in the predefined age groups and differentiation by
110 gender only indirectly. The G-DRG data provided by InEK have been described in detail
111 elsewhere (14).

112 Cohort selection

113 We included hospitalizations with a secondary diagnosis of RT-PCR proven COVID-19
114 infection (ICD-10-GM: U07.1), aged over 15 years. We excluded hospitalizations 15.525
115 (9,1%) with hospital transfer and unknown discharge status from our analysis. We identified
116 hospitalizations with acute kidney injury by their corresponding ICD-10-GM codes (S1
117 Table). We included hospitalizations with acute kidney injury stages 1 to 3 (AKIN 1 to 3) (15).
118 We further searched for OPS codes indicating hemodialysis and mechanical ventilation (S1
119 Table). The survival status at the end of each hospitalization was obtained by discharge
120 type. The observation period was from 01.02.2020 throughout 31.12.2020.

121 Statistical analysis

122 We calculated crude, age-specific and age-standardized hospitalization rates (ASR) per
123 100.000 person years and the respective 95% confidence intervals (95% CI). We used the
124 standard population of Germany in 2011 (16), provided by the Federal Bureau of Statistics
125 (DESTATIS), for direct age-standardization (S2 Table). We further calculated standardized
126 rate ratios (SRR), with their respective confidence intervals. Continuous variables are
127 reported with standard deviation (SD). Categorical data is reported in absolute numbers and
128 percentages. We used the ICD-10 version of the Elixhauser comorbidity index (ECI) to assess
129 comorbidities (17). We excluded acute kidney injury as a comorbidity. All data analysis was

130 carried out using R (Version 3.6.3) (18), for direct age-standardization the epitools package

131 (19) was used, contingency tables were evaluated using the epiR package (20).

Results

General characteristics and age-standardized rates

In 2020, there were 16.776.845 hospitalizations in German hospitals. We detected 154.170 hospitalizations with RT-PCR proven COVID-19 diagnosis throughout the observation period. There were 79.781 (51,8%) male and 74.382 (48,2%) female patients hospitalized, respectively (Table 1). In 29.329 (19,0%) of the COVID-19 associated hospitalizations the treatment included an intensive care unit (ICU) stay. The age-standardized hospitalization rate for COVID-19 in Germany was 232,8 per 100.000 person years (95% CI 231,6-233,9) in 2020. Most hospitalizations (1394,1 per 100.000 person years) occurred in the age group of 80 years and older (Fig 1).

	AKI		ICU		Overall	
N	16.773		29.329		154.170	
Gender	%	n	%	n	%	n
male	61,5 (10.308)		62,6 (18.361)		51,8 (79.781)	
female	38,5 (6.463)		37,4 (10.965)		48,2 (74.382)	
Age group (years)	%	n	%	n	%	n
16-17	0,0%	1	0,1%	38	0,3%	472
18-29	0,4%	70	1,7%	493	4,0%	6143
30-39	0,7%	112	2,8%	829	5,3%	8185
40-49	1,9%	326	5,8%	1704	7,5%	11601
50-54	2,6%	443	5,8%	1688	6,2%	9537
55-59	4,5%	754	7,9%	2312	7,5%	11602
60-64	6,8%	1134	9,6%	2818	7,7%	11858
65-74	20,3%	3408	21,8%	6398	16,5%	25418
75-79	17,0%	2851	14,6%	4282	11,7%	18045
80+	45,8%	7674	29,9%	8767	33,3%	51309
length of stay (days, SD)	18,4 (16,9)		18,3 (16,7)		11,3 (11,9)	
Elixhauser comorbidity index (% n)	%	n	%	n	%	n
0	60 (10.041)		65 (18.918)		65 (99.783)	
1-4	24 (4.029)		25 (7.186)		25 (39.117)	
>=5	16 (2.703)		10 (3.225)		10 (15.270)	
mean (SD)	2,0 (3,8)		1,6 (3,8)		1,2 (3,1)	

151 Table 1. General characteristics of COVID-19 hospitalizations in Germany 2020.

152 ICU: intensive care unit - hospitalizations with intensive care treatment during the hospital
153 stay, AKI: acute kidney injury - hospitalizations with acute kidney injury (Acute kidney injury
154 network Stage 1-3), SD: standard deviation

155

156 Fig 1. Age-specific rates of COVID-19 hospitalizations in Germany 2020 (per 100.000 person
157 years)

158 Hospital incidence of acute kidney injury

159 Acute kidney injury, including AKI Stages 1-3, was diagnosed in 16.773 (10,9%) of the
 160 hospitalized cases with COVID-19. The ASR for AKI was 25.8 (95%CI 25.4-26.2) per 100.000
 161 person years (Table 2). While men and women were equally distributed among those
 162 hospitalized for COVID-19, men were more affected by AKI than women. The relative risk of
 163 AKI for males was 1,49 (95%CI 1,44-1,53) compared to females hospitalized with COVID-19
 164 (S2 Table). We determined 10.310 (61,5%) male and 6.463 (38,5%) female hospitalizations
 165 with acute kidney injury, respectively (Table 1). The proportion of the severity of acute
 166 kidney injury was distributed as follows: 32,0% (n= 5.407) developed AKI Stage 1, AKI Stage
 167 2 was present in 27,4 % (n= 4.625) and in 40,6% (n= 6.842) AKI Stage 3 was coded. There
 168 were 101 hospitalizations with more than one code for AKI. When acute kidney injury was
 169 present during hospital stay, 8.374 (49,9 %) needed intensive care. Furthermore, mechanical
 170 ventilation was required in 7.050 (42,0 %) hospitalizations with acute kidney injury (Table 2).
 171 The relative risk for hospitalizations with AKI to be treated in an intensive care unit was 3,27
 172 (95%CI 3,21-3,34) (Table 3).

	AKI		ICU		Overall	
	n	%	n	%	n	%
Overall	16.773 (10,9%)		29.329 (19,0%)		154.170 (-)	
Renal replacement therapy	3.443 (20,5%)		3.046 (10,4%)		-	
males	2.635	76,5%	2.335	76,7%	-	-
females	808	23,5%	711	23,3%	-	-
In-hospital mortality	9.717 (57,9%)		12.322 (40,6%)		30.300 (19,7%)	
males	6.283	64,7%	7.990	64,8%	17.635	58,2%
females	3.434	35,3%	4.330	35,2%	12.665	41,8%
AKI Stages						
1	5.407	32,0%	1.865	20,3%	-	
2	4.625	27,4%	2.011	21,8%	-	
3	6.842	40,6%	5.333	57,9%	-	
Chronic kidney disease	5.524 (32,9%)		5.365 (18,3%)		23.380 (15,2%)	
G3	3.638	21,7%	3.225	11,0%	15.270	9,9%
G4	1.490	8,9%	1.084	3,7%	4.535	2,9%
G5	396	2,4%	1.056	3,6%	3.575	2,3%
Mechanical ventilation	7.050 (42,0%)		17.144 (58,5%)		-	
males	5.052	71,6%	11.508	67,1%	-	
females	1.998	28,3%	5.634	32,9%	-	
Age-standardized rate (per 100.000 PYRs, 95% CI)	25,8 (25,4-26,2)		44,0 (43,5-44,5)		232,8 (231,6-233,9)	

173

174 Table 2: Results COVID-19 hospitalizations in Germany 2020,

175 ICU: intensive care unit - hospitalizations with intensive care treatment during the hospital

176 stay, AKI: acute kidney injury - hospitalizations with acute kidney injury (acute kidney injury

177 network, Stage 1-3), 95%CI: 95 % confidence interval, PYRs: person years

178

179

180

	ICU		Non-ICU		Overall
	N	%	N	%	n
AKI	8.374	49,9	8.399	50,1	16.773
Non-AKI	20.955	15,3%	116.442	84,7%	137.397
Overall	29.329	19,0%	124.841	81,0%	154.170
	Deceased		Alive		Overall
	N	%	N	%	N
AKI	9.717	57,9%	7.056	42,1%	16.773
Non-AKI	20.583	15,0%	116.814	85,0%	137.397
Overall	30.300	19,7%	123.870	80,3%	154.170

181

182 Table 3: Contingency table for AKI and risk of ICU admission or in-hospital mortality,
183 ICU: intensive care unit - hospitalizations with intensive care treatment during the hospital
184 stay, AKI: acute kidney injury - hospitalizations with acute kidney injury (acute kidney injury
185 network, Stage 1-3)

186 Renal replacement therapy

187 When acute kidney injury was present, renal replacement therapy (RRT) was performed in
188 3.443 hospitalizations, 20,5% of hospitalizations with AKI and 2,2% of all COVID-19
189 associated hospitalizations. Furthermore, when RRT was conducted, mechanical ventilation
190 was needed in 2.380 (69,1%) cases. The modality of renal replacement therapy was
191 intermittent RRT in 230 (6,7%), and continuous or prolonged intermittent RRT in 3.213
192 (93,3%) hospitalizations, respectively. In 828 (24,0%) hospitalizations more than one
193 procedure code indicating RRT was present.

194 Chronic kidney disease (CKD Stages 3 to 5) was present in 23.380 (15.2%) hospitalizations
195 with AKI. We observed 3.638 (21,7%) hospitalizations with AKI and CKD Stage G3, in 1.490
196 (8.9%) hospitalizations CKD G4 was prevalent and 396 (2,4%) had CKD G5, respectively.

197 In-hospital mortality

198

199 For all hospitalizations with COVID-19, the in-hospital mortality amounted to 19,7% (n=
200 30.300). Of these, 58,2% (n= 17.635) were men and 41,8% (n=12.665) were women (Table
201 2), respectively. The relative risk for in-hospital mortality for men amounted to 1,30 (95%CI
202 1,27-1,33) compared to women (S3 Table). The ASR for in-hospital mortality was 47,7
203 (95%CI 47,2-48,3) per 100.000 person years. Most deaths (511,2 per 100.000 person years)
204 were observed in the age group over 80 years of age (Fig S1). When AKI was present, 9.717
205 died, accounting for 57,9% of deaths in this group (Table 2), the relative risk for in-hospital
206 mortality was 3,87 (95%CI 3,80-3,94) when AKI occurred (Table 3). Moreover, when
207 hemodialysis was performed, 2.891 died, which amounts to 61,4% of all hospitalizations
208 with RRT.

209

210 Length of stay

211 The mean length of stay (LOS) for hospitalizations with COVID-19 was 11,3 days (SD 11,9).
 212 When acute kidney injury was coded, the LOS increased to 18,4 days (SD 16,9). For cases
 213 that had an ICU stay the mean LOS was 18,3 days (SD 16,7) (Table 1).

214 Time course of hospitalization rates and in-hospital mortality

215

216 The age-standardized hospitalization rates for COVID-19 took a bimodal course during the
 217 observation period. The first peak of ASR occurred in April 2020 (23,95 per 100.000 person
 218 years (95%CI 23,58-24,33)), after the ASR rose steadily beginning in February. Subsequently,
 219 ASR for COVID-19 hospitalizations peaked again in November 2020 (72,82 per 100.000
 220 person years (95%CI 72,17-73,48)). In comparison to the first peak, ASR rose steadily for two
 221 months before reaching the highest rates (Fig 2A).

222 The ASR for AKI and AKI-related mortality took a flatter curve, but overall follow a similar
 223 bimodal course. The ASR for AKI and AKI-related mortality reached their peak in March 2020
 224 (for AKI 3,4 per 100.000 person years (95%CI 3,27-3,55), which was also when AKI-related
 225 mortality reached 2,07 (95%CI 1,96-2,18), respectively). In November 2020 ASR tipped again
 226 when ASR for AKI stood at 8,07 per 100.000 person years (95%CI 7,85-8,29), and the ASR for
 227 AKI-related mortality rose to 4,65 (95%CI 4,49-4,82)) (Fig 2A).

228 The standardized rate ratios (SRR) for AKI and AKI-related mortality with the overall ASR for
 229 COVID-19 hospitalizations in the denominator, actually decreased throughout the
 230 observation period (Fig 2B) and remained lower in autumn than they were in spring. In

contrast to this finding, the ASR and in particular the SRR for overall mortality in COVID-19 hospitalizations rose sharply again as early as September 2020 (Fig 3A and 3B).

The distribution of age groups varied throughout the observation period. In particular, the age group of 80 years and above were most prevalent in the months of April, November and December (Fig S4). Hospitalizations in which AKI was coded, were proportionately much older, with the 80 years and above age group being the most represented (Fig S5).

Fig 2: A) Time course of age-standardized rates (per 100.00 person years) of overall hospitalization, AKI and AKI-related mortality for COVID-19 in Germany (2020); B) Standardized rate ratios (SRR) of AKI age-standardized rates (per 100.00 person years) and AKI-related mortality in relation to the overall age-standardized COVID-19 hospitalization rate in Germany (2020)

Fig 3: A) Time course of age-standardized rates (per 100.00 person years) of overall hospitalization and overall mortality for COVID-19 in Germany (2020); B) Standardized rate ratios (SRR) of overall mortality age-standardized rates (per 100.00 person years) in relation to the overall age-standardized COVID-19 hospitalization rate in Germany (2020)

Comorbidities

The Elixhauser comorbidity index (ECI) varied among the different groups. The mean ECI for all COVID-19 associated hospitalizations was 1,2 (SD 3,1). For hospitalizations requiring intensive care the mean ECI was 1,6 (SD 3,8). When acute kidney injury was present the ECI increased to 2,0 (SD 3,8). In general, the four most common coded comorbidities were uncomplicated hypertension (35,3%), fluid and electrolyte disorders (20,6%), uncomplicated diabetes mellitus (13,3%) and cardiac arrhythmias (10,0%) (Fig 4). When acute kidney injury

253 or an ICU stay were coded, cardiac arrhythmias were relatively more prevalent compared to
254 all hospitalizations with COVID-19 (Fig S2, S3).

255 Fig 4: Relative frequencies of comorbidities in COVID-19 hospitalizations in Germany 2020.

256 chf: congestive heart failure; carit: cardiac arrhythmias; valv: valvular disease; pcd: pulmonary circulation
257 disorders; pvd: peripheral vascular disorders; hypunc: hypertension - uncomplicated; hypc: hypertension
258 - complicated; para: paralysis; ond: other neurological disorders; cpd: chronic pulmonary disease;
259 diabunc: diabetes -uncomplicated; diabc: diabetes- complicated; hypothy: hypothyroidism; ld: liver
260 disease; pud: peptic ulcer disease- excluding bleeding; aids: AIDS/HIV; lymph: lymphoma; metacanc:
261 metastatic cancer; solidtum: solid tumour: without metastasis; rheumd: rheumatoid arthritis/collaged
262 vascular disease; coag: coagulopathy; obes: obesity; wloss: weight loss; fed: fluid and electrolyte
263 disorders; blane: blood loss anaemia; dane: deficiency anaemia; alcohol: alcohol abuse; drug: drug abuse;
264 psycho: psychoses; depre: depression;
265

266 Discussion

267 Our study for the first time provides nationwide data on COVID-19 hospitalizations and
268 acute kidney injury in Germany in 2020. The key findings that emerge from our data are as
269 follows. The highest proportion of hospitalizations associated with COVID-19 were in the
270 age group over 80 years. The gender distribution was equal in COVID-19 related
271 hospitalization, however, we observed that men more often developed acute kidney injury
272 (RR 1,49 (95%CI 1,44-1,53)), needed ICU care and had a higher risk of in-hospital mortality
273 (RR: 1,30 (95%CI 1,27-1,33)) than women. Our results thus exhibit a gender bias. This is
274 consistent with a meta-analysis including 3.111.714 COVID-19 associated hospitalizations
275 worldwide, which identified male sex as a risk factor for death and ICU-admission, despite
276 the gender ratio being equal at the time of admission (21). Different underlying
277 mechanisms - from hormonal, genetic to behavioral effects and risk factor prevalence –
278 have been discussed in the literature (21,22).

279 Overall, 19 % of all hospitalizations needed intensive care treatment. This fraction was
280 particularly high in patients with acute kidney injury. This finding is in line with other studies
281 (23,24). There are no clearly defined criteria for ICU admission in COVID-19 hospitalized
282 patients. Germany possesses the highest capacity of intensive care beds in all OECD-
283 countries. Despite the presumably higher availability of ICU capacity, this fact did not lead to
284 higher utilization of these capacities. This could be an indicator that the percentage of
285 critically ill patients was similar compared to different countries (23).

286 Occurrence of AKI considerably differs in previous studies, partly due to a different
287 definition of AKI. Our analysis showed that 10.9% of all hospitalizations experienced acute
288 kidney injury. The incidence of AKI in this national series is lower than what has been
289 reported in regionally confined studies from the United States (8,9,23). A meta-analysis by
290 Gabarre et al. (2) rendered similar results to our figures. They observed an average AKI
291 incidence of 11% (95%CI 8–17%) overall, with highest ranges in the critically ill (23% (95%CI
292 14– 35%)). Nevertheless, the age structure, risk factor prevalence and the burden of COVID-
293 19 during the observation period differ relevantly between countries and the AKI rate is
294 therefore only comparable to a limited extend.

295 A large proportion of patients with acute kidney injury suffered severe kidney injury (AKIN
296 Stage 3: 40,6%), this is consistent with previous findings (9). In the group of hospitalization
297 with AKI 49,9% required ICU admission compared to 15,2 % of patients without AKI. The
298 relative risk to be treated in an ICU was 3,27 for AKI patients. Moreover, in the group with
299 AKI, 42,0 % required mechanical ventilation. Data from the early phase of the pandemic in
300 New York state estimated that 53,6% of AKI patients needed invasive ventilation (10). This
301 higher numbers are likely reflective of more severe disease outcomes in patients with AKI.

302 RRT was required in 2,2% of all hospitalizations. Among patients with AKI 20,5% required
 303 RRT. This figure is consistent with data from various studies (6,9,25). The majority (88,5%) of
 304 the RRT was performed in the intensive care unit. 69,1 % of all patients requiring dialysis
 305 needed invasive ventilation. Similar findings were reported in a multi-center cohort study
 306 from the United States (6). Previous studies suggested that there is an association between
 307 mechanical ventilation, AKI and RRT. RRT often occurs around time of intubation, suggesting
 308 a role for altered hemodynamics in this situation (6,10). Hence, vasopressors are often
 309 initiated around this time.

310 The overall in-hospital mortality for COVID-19 associated hospitalizations vary across
 311 different countries and cohorts, showing differences in testing and case identification,
 312 variable thresholds for hospitalization and staff capacities. Therefore, differences in in-
 313 hospital mortality ranged between 15 to 20% (26,27). Our analysis showed that 30.300
 314 (19.7%) of hospitalizations with COVID-19 ultimately deceased, of 154.170 initially admitted
 315 to hospital. In-hospital mortality was 57.9% among patients with AKI versus 15% among
 316 those without AKI. This finding underlines the poor prognosis of these patients and the
 317 severity of disease.

318 The age-standardized hospitalization rate due to COVID-19 in 2020 was bimodally shaped,
 319 with peak rates in April and November. This observation is congruent with the incidence
 320 figures reported by the Robert Koch Institute (28). The first peak with increasing mortality
 321 rates in March and April was followed by a decline in mortality rates and a concomitant
 322 decrease in hospital admissions. Similar results have already been demonstrated in various
 323 studies from other countries. In a data-analysis from the United States a decrease in the
 324 risk-adjusted mortality was observed, ranging from 16.56 % to 9.29% in the early period of

325 this study (January through April 2020) compared with the later period (May through June
326 2020) (29). Further, national ICU data from the United Kingdom – published as a preprint up
327 to now - confirmed this finding. The authors found a reduction in mortality rates from 41,4%
328 in March 2020 to 24,8% in June 2020 (30). The underlying reason for the decrease of
329 mortality rates is not obvious and certainly multifactorial. One important factor was
330 certainly the concomitant decline in the incidence rate in the UK and the US. For example, a
331 large US study of health insurance data, involving more than 38.517 patients, revealed that
332 the strongest determinant of improvements in in-hospital outcome was a decline in
333 community rates of infection (29). Other reasons might be a shift in demographics,
334 experience in physicians to early diagnose and treat COVID-19 patients, hospitals and staff
335 became less overwhelmed during time. In our data during the second peak in COVID-19
336 hospitalizations, which was more pronounced than the first, the in-hospital mortality rate
337 increased steadily from September to December and exceeded the COVID-19 associated in-
338 hospital mortality in March and April markedly (5,36 per 100.000 person years in April and
339 16,15 per 100.000 person years in December). One can only speculate about the factors that
340 led to this development. One, but certainly not the only, explanation could be a different
341 age distribution of patients admitted to the hospital with a higher proportion of older
342 patients in November and December, as in our data (Fig S4, Fig S5). Further, multiple factors
343 might have influenced in-hospital mortality. The increasing number of patients in need of
344 critical care could have overwhelmed hospitals regionally, which happened for example in
345 Saxony, Germany in December 2020. As already mentioned, an American study has shown
346 that hospitals did better when the prevalence of COVID-19 in their surrounding
347 communities was lower(29). Another contributing factor could have been staff shortages
348 driven by COVID-19 infections, school lockdowns, quarantine regulations and the necessity

to take care of relatives infected with COVID-19 or in quarantine. In contrast to the development discussed above, the ASR for AKI and AKI-related mortality had a disproportionately smaller increase and were already declining in December. The age distribution in our cohort was similar among all hospitalized patients, with a higher proportion of elderly patients in the second peak in October, November and December in comparison to February, March and April. Thus, differences in age distribution is not a good explanation for this finding (S4 Fig and S5). At this point, it must be said again that multiple factors could have influenced the ASR for AKI und AKI-related mortality. Apart from differences in the patient population or age distribution, changes in the treatment strategy - e.g., the early use of drug therapies for patients with an increased risk of severe COVID-19 courses.

The mean length of stay (LOS- discharged or dead) of all patients was 11,3 days and increased with AKI to 18,4 days. LOS varies in different studies, and - according to a systematic review by Rees et al. (31) - the median LOS was 14 days in China, compared with 5 (IQR 3–9) days outside of China. Similar figures were reported by Fisher et al. (8). This may be explained by many differences in criteria for admission and discharge between countries, and different timings in the course of the pandemic. Hospital capacities in Germany were not overwhelmed by the pandemic, and the pressure to discharge patients might have been lower. The most comprehensive analysis of German patients to date included 10.021 patients with a mean LOS of 14,3 days (32). This was longer than in our analysis, an explanation for the discrepancy could be timing of data collection. Karagiannidis et al. collected their data at the beginning of the pandemic. Due to an increasing experience in

371 treating COVID-19 patients and new treatment options, the length of stay consequently
372 declined.

373 The observed comorbidities varied between the different groups. Hypertension, diabetes
374 mellitus, fluid and electrolyte disorders and cardiac arrhythmias were the most commonly
375 coded comorbidities. This finding is plausible, as these are the most common comorbidities
376 in patients with chronic kidney disease (33) and likewise known risk factors for
377 hospitalization with COVID-19 (34). Cardiac arrhythmias became more prevalent in
378 hospitalizations with AKI. Cardiac arrhythmias are a common finding in COVID-19, in
379 particular with an increasing number of comorbidities (35).

380 [Strengths and limitations](#)

381 The major strength of this study is that we provide a nationwide population-based view on
382 COVID-19 hospitalizations with acute kidney injury in Germany. We retrieved DRG-data
383 covering virtually every hospital in Germany. In this study, we use routine hospitalization
384 data, which is lacking clinical detail. This might lead to confounding that we could not adjust
385 for. The InEK provides aggregated data due to data safety precautions, which is fully
386 anonymized. It is, therefore, possible that this could lead to bias caused by readmission,
387 though this possibility is limited, because of the severity of most cases and our efforts to
388 exclude readmissions from the dataset. Another important fact to consider, when analyzing
389 routine data, is the observation period. In our analysis the observation period ends in the
390 midst of the second wave of the COVID-19 pandemic in Germany. This will lead to bias, as
391 the outcome of these cases remains unknown, in particular for hospitalizations in the last
392 month of the observation period.

393

395 Bibliography

- 396 1. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
397 Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients
398 Hospitalized with COVID-19 in the New York City Area. JAMA - Journal of the
399 American Medical Association. 2020;323(20):2052–9.
- 400 2. Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury
401 in critically ill patients with COVID-19. Intensive Care Medicine [Internet].
402 2020;46(7):1339–48. Available from: <https://doi.org/10.1007/s00134-020-06153-9>
- 403 3. Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not
404 result in acute kidney injury: An analysis of 116 hospitalized patients from Wuhan,
405 China. American Journal of Nephrology. 2020;51(5):343–8.
- 406 4. Yang X, Jin Y, Li R, Zhang Z, Sun R, Chen D. Prevalence and impact of acute renal
407 impairment on COVID-19: A systematic review and meta-analysis. Critical Care.
408 2020;24(1):1–8.
- 409 5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
410 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
411 study. The Lancet [Internet]. 2020;395(10229):1054–62. Available from:
412 [http://dx.doi.org/10.1016/S0140-6736\(20\)30566-3](http://dx.doi.org/10.1016/S0140-6736(20)30566-3)
- 413 6. Gupta S, Coca SG, Chan L, Melamed ML, Brenner SK, Hayek SS, et al. AKI treated with
414 renal replacement therapy in critically ill patients with COVID-19. Journal of the
415 American Society of Nephrology. 2021;32(1):161–76.
- 416 7. Thakkar J, Chand S, Aboodi MS, Gone AR, Alahiri E, Schechter DE, et al. Characteristics,
417 Outcomes and 60-Day Hospital Mortality of ICU Patients with COVID-19 and Acute
418 Kidney Injury. Kidney360. 2020;1(12):1339–44.

- 419 8. Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TS, et al. AKI in Hospitalized
420 Patients with and without COVID-19: A Comparison Study. Journal of the American
421 Society of Nephrology [Internet]. 2020 Sep 1;31(9):2145 LP – 2157. Available from:
422 <http://jasn.asnjournals.org/content/31/9/2145.abstract>
- 423 9. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in hospitalized
424 patients with COVID-19. Journal of the American Society of Nephrology.
425 2021;32(1):151–60.
- 426 10. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury
427 in patients hospitalized with COVID-19. Kidney International. 2020;98(1):209–18.
- 428 11. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al.
429 Case characteristics, resource use, and outcomes of 10⁴ patients with COVID-19
430 admitted to 920 German hospitals: an observational study. The Lancet Respiratory
431 Medicine [Internet]. 2020 [cited 2021 Mar 11];8(9):853–62. Available from:
432 www.thelancet.com/respiratoryVol
- 433 12. Graubner B, Auhuber TC. ICD-10-GM Version 2020, Systematisches Verzeichnis,
434 Internationale statistische Klassifikation der Krankheiten und verwandter
435 Gesundheitsprobleme, 10. Revision, Stand: 20. September 2019 [Internet]. Köln:
436 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) im Auftrag des
437 Bundesministeriums für Gesundheit (BMG) unter Beteiligung der Arbeitsgruppe ICD
438 des Kuratoriums für Fragen der Klassifikation im Gesundheitswesen (KKG); 2019. p.
439 September 2019. Available from: www.dimdi.de – Klassifikationen – Downloads –
440 ICD-10-GM – Version 2021
- 441 13. Operationen- und Prozedurenschlüssel Internationale Klassifikation der Prozeduren
442 in der Medizin (OPS) Band 1: Systematisches Verzeichnis [Internet]. Bundesinstitut für

- 443 Arzneimittel und Medizinprodukte (BfArM) im Auftrag des Bundesministeriums für
444 Gesundheit (BMG) unter Beteiligung der Arbeitsgruppe ICD des Kuratoriums für
445 Fragen der Klassifikation im Gesundheitswesen (KKG); 2020. 740. Available from:
446 <https://www.dimdi.de/dynamic/de/klassifikationen/icd/icd-10-gm/>
- 447 14. Busse R, Nimptsch U. COVID-19-Pandemie: Historisch niedrige Bettenauslastung.
448 Deutsches Aerzteblatt Online. 2021;118(10):10–3.
- 449 15. Levin A, Warnock DG, Mehta RL, Kellum JA, Shah S v., Molitoris BA, et al. Improving
450 Outcomes From Acute Kidney Injury: Report of an Initiative. American Journal of
451 Kidney Diseases. 2007;50(1):1–4.
- 452 16. Gesundheitsberichterstattung des Bundes [Internet]. 2021. Available from:
453 https://www.gbe-bund.de/gbe/pkg_isgbe5.prc_isgbe
- 454 17. Quan H, Sundararajan V, Halfon P, Fong A. Coding algorithms for defining
455 comorbidities in. Medical Care [Internet]. 2005;43(11). Available from:
456 [http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Coding+Algorithms](http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Coding+Algorithms+for+Defining+Comorbidities+in#1%5Cnhttp://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Coding+algorithms+for+defining+comorbidities+in#1)
457 [+for+Defining+Comorbidities+in#1%5Cnhttp://scholar.google.com/scholar?hl=en&bt](http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Coding+algorithms+for+defining+comorbidities+in#1)
458 [nG=Search&q=intitle:Coding+algorithms+for+defining+comorbidities+in#1](http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Coding+algorithms+for+defining+comorbidities+in#1)
- 459 18. Team RC. R: A Language and Environment for Statistical Computing [Internet].
460 Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: [www.r-](http://www.r-project.org)
461 [project.org](http://www.r-project.org)
- 462 19. Tomas J. Aragon. epitools: Epidemiology Tools. R package version 0.5-10.1. 2020.
- 463 20. Stevenson M, Sergeant E. epiR - Tools for the Analysis of Epidemiological Data. 2021.
- 464 21. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et
465 al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and

- 466 ITU admission. Nature Communications [Internet]. 2020;11(1):1–10. Available from:
467 <http://dx.doi.org/10.1038/s41467-020-19741-6>
- 468 22. Kelada M, Anto A, Dave K, Saleh SN. The Role of Sex in the Risk of Mortality From
469 COVID-19 Amongst Adult Patients: A Systematic Review. Cureus. 2020;12(8).
- 470 23. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
471 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients
472 Hospitalized With COVID-19 in the New York City Area. JAMA [Internet].
473 2020;323:2052–9. Available from: <https://jamanetwork.com/>
- 474 24. Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TS, et al. AKI in Hospitalized
475 Patients with and without COVID-19: A Comparison Study. Journal of the American
476 Society of Nephrology [Internet]. 2020 Sep 1;31(9):2145 LP – 2157. Available from:
477 <http://jasn.asnjournals.org/content/31/9/2145.abstract>
- 478 25. Richards-Belle A, Orzechowska I, Doidge J, Thomas K, Harrison DA, Koelewyn A, et al.
479 Critical care outcomes, for the first 200 patients with confirmed COVID-19, in
480 England, Wales and Northern Ireland: A report from the ICNARC Case Mix
481 Programme. Journal of the Intensive Care Society. 2020;0(0):1–10.
- 482 26. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
483 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A
484 Review. JAMA - Journal of the American Medical Association. 2020;324(8):782–93.
- 485 27. Sorci G, Faivre B, Morand S. Explaining among-country variation in COVID-19 case
486 fatality rate. Scientific Reports. 2020 Dec 1;10(1).
- 487 28. Robert Koch Institut. Total overview of cases, deaths, and 7-day incidences reported
488 per day to the RKI by state and county. [Internet]. 2021. Available from:
489 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Daten/Fallzahlen_

- 490 Daten.html;jsessionid=4D411DFBB2E2575A9CD1F5504E7CE3BC.internet052?nn=134
- 491 90888
- 492 29. Asch DA, Sheils NE, Islam MN, Chen Y, Werner RM, Buresh J, et al. Variation in US
- 493 Hospital Mortality Rates for Patients Admitted with COVID-19 during the First 6
- 494 Months of the Pandemic. JAMA Internal Medicine. 2020;19104(4):471–8.
- 495 30. Dennis JM, McGovern AP, Vollmer SJ, Mateen BA. Improving COVID-19 critical care
- 496 mortality over time in England: A national cohort study, March to June 2020.
- 497 medRxiv. 2020;44(0).
- 498 31. Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, Pearson CAB, et al. COVID-
- 499 19 length of hospital stay: A systematic review and data synthesis. medRxiv. 2020;
- 500 32. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al.
- 501 Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19
- 502 admitted to 920 German hospitals: an observational study. The Lancet Respiratory
- 503 medicine [Internet]. 2020 Sep [cited 2021 Mar 11];8(9):853–62. Available from:
- 504 www.thelancet.com/respiratoryVol
- 505 33. Reichel H, Zee J, Tu C, Young E, Pisoni RL, Stengel B, et al. Chronic kidney disease
- 506 progression and mortality risk profiles in Germany: Results from the Chronic Kidney
- 507 Disease Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation.
- 508 2020 May 1;35(5):803–10.
- 509 34. Ioannou GN, Locke E, Green P, Berry K, O’Hare AM, Shah JA, et al. Risk Factors for
- 510 Hospitalization, Mechanical Ventilation, or Death Among 107131 US Veterans With
- 511 SARS-CoV-2 Infection. JAMA network open. 2020;3(9):e2022310.

- 512 35. Coromilas EJ, Kochav S, Goldenthal I, Biviano A, Garan H, Goldberg S, et al.
513 Worldwide Survey of COVID-19 Associated Arrhythmias. Circulation: Arrhythmia and
514 Electrophysiology. 2021;(March):285–95.
515
516

517 Supporting information

518 S1 Fig. Age-specific mortality rates of COVID-19 hospitalizations in Germany 2020 (per

519 100.000 person years)

520 S2 Fig. Relative frequencies of comorbidities in COVID-19 hospitalizations with AKI in

521 Germany 2020.

522 chf: congestive heart failure; carit: cardiac arrhythmias; valv: valvular disease; pcd: pulmonary circulation
523 disorders; pvd: peripheral vascular disorders; hypunc: hypertension - uncomplicated; hypc: hypertension
524 - complicated; para: paralysis; ond: other neurological disorders; cpd: chronic pulmonary disease;
525 diabunc: diabetes -uncomplicated; diabc: diabetes- complicated; hypothy: hypothyroidism; ld: liver
526 disease; pud: peptic ulcer disease- excluding bleeding; aids: AIDS/HIV; lymph: lymphoma; metacanc:
527 metastatic cancer; solidtum: solid tumour: without metastasis; rheumd: rheumatoid arthritis/collaged
528 vascular disease; coag: coagulopathy; obes: obesity; wloss: weight loss; fed: fluid and electrolyte
529 disorders; blane: blood loss anaemia; dane: deficiency anaemia; alcohol: alcohol abuse; drug: drug abuse;
530 psycho: psychoses; depre: depression;

531

532 S3 Fig. Relative frequencies of comorbidities in COVID-19 hospitalizations with ICU

533 treatment in Germany 2020.

534 chf: congestive heart failure; carit: cardiac arrhythmias; valv: valvular disease; pcd: pulmonary circulation
535 disorders; pvd: peripheral vascular disorders; hypunc: hypertension - uncomplicated; hypc: hypertension
536 - complicated; para: paralysis; ond: other neurological disorders; cpd: chronic pulmonary disease;
537 diabunc: diabetes -uncomplicated; diabc: diabetes- complicated; hypothy: hypothyroidism; ld: liver
538 disease; pud: peptic ulcer disease- excluding bleeding; aids: AIDS/HIV; lymph: lymphoma; metacanc:
539 metastatic cancer; solidtum: solid tumour: without metastasis; rheumd: rheumatoid arthritis/collaged
540 vascular disease; coag: coagulopathy; obes: obesity; wloss: weight loss; fed: fluid and electrolyte
541 disorders; blane: blood loss anaemia; dane: deficiency anaemia; alcohol: alcohol abuse; drug: drug abuse;
542 psycho: psychoses; depre: depression;

543

544 S4 Fig. Percentage distribution of age groups during the observation period (Overall COVID-

545 19)

546 S5 Fig. Percentage distribution of age groups during the observation period (AKI)

547 S1 Table. List of ICD-10-GM and OPS Codes, version 2020

548 S2 Table. Contingency table AKI by sex

549 S3 Table. Contingency table in-hospital mortality by sex

A

B

A

B